跳至主要内容
临床试验/NCT03847714
NCT03847714已完成不适用

Probiotics in Dementia

Medical University of Graz1 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2019年6月15日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
17
试验地点
1
主要终点
Butyrate producing bacteria

研究概览

简要总结

Dementia is associated with changes in gut microbiome composition, gut barrier dysfunction, intestinal inflammation and systemic inflammation. Probiotics are a possibility to modulate the gut-brain axis. In this study the effect of probiotics on the gut microbiome and, gut barrier function, inflammation and cognitive dysfunction will be studied.

详细描述

Dementia is a disease that presents with deterioration in memory, thinking, behaviour and the ability to perform everyday activities. Worldwide 47.5 million people are affected and incidence of dementia is increasing. Dementia leads to disability and dependency among older people worldwide and thereby has a huge physical, psychological, social and economic impact on caregivers, families and society. Alzheimer's disease (AD) is the most common form of dementia accounting for 60-70% of the cases; other forms include Lewy body dementia, frontotemporal dementia, vascular dementia and Parkinson's disease with dementia. In AD, pathologic protein aggregates of amyloid beta and hyperphosphorylated tangles of tau-protein which deposit as neurofibrillary tangles are typical features. This leads to neuroinflammation, mainly mediated by the innate immune system. The most important cells in this process are microglia cells, which represent the resident macrophages of the brain. Although microglia is able to remove extracellular amyloid beta, in later stages of the disease cells remain in a dystrophic state and cannot exert their beneficial functions. Microglia maturation and function is critically dependent on short-chain fatty acids produced by the gut microbiome and therefore highlights the microbiome as a potential diagnostic and therapeutic target in dementia.

The role of the commensal microbial population of the human body - especially the intestinal microbiome - in various diseases is emerging due to the development of advanced analysis techniques. Recently the concept of the gut brain-axis has been established. Several pathways including the autonomic nervous system, the enteric nervous system, the neuroendocrine system and the immune system allow a communication between gut and brain but may also be involved in disease development.

During ageing, the gut microbiome composition undergoes changes. A decrease in diversity, a loss of beneficial taxa and an increase of facultative pathogens has been described. Diet and the place of residence play an important role in the shaping of the microbiome. Aging is also associated with inflammation - often termed as "inflammaging" associated with an increase in gut permeability, mucosal inflammation and bacterial translocation.

Since the main risk factor for developing dementia, especially AD, is aging, it is very likely that the gut-brain axis is critically involved in dementia development.

Animal studies so far suggest that AD is associated with changes in the gut microbiome composition with a decrease in beneficial, anti-inflammatory genera. Furthermore, genetic alterations in amyloid genes can influence microbiome composition in mice, pointing towards a vicious cycle in AD development.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

similar looking and tasting placebo

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age >18 years
  • Dementia of Alzheimer type and mixed type (diagnosis by a board-certified neurologist/psychiatrist and according to ICD10)
  • Mini Mental State Examination 21-26
  • Stable treatment with anti-dementia drugs including phytotherapeutics (>3 months) or no intention to start anti-dementia drugs
  • Informed consent

排除标准

  • Other forms of dementia
  • Inflammatory bowel diseases
  • Liver cirrhosis
  • Antibiotic treatment within the last 4 weeks
  • Febrile illness within the last 4 weeks
  • Acute hospital admission for dementia-unrelated reasons within the last 4 weeks
  • Dysphagia
  • Any other condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol

研究组 & 干预措施

Probiotic

Active Comparator

Bifidobacterium bifidum W23, B. lactis W51, B. lactis W52, Lactobacillus acidophilus W22, L. casei W56, L. paracasei W20, L. plantarum W62, L. salivarius W24, Lactococcus lactis W19, 7.5 × 109 Colony Forming Units/g twice daily dissolved in water

干预措施: Omni-Biotic Stress Repair (Dietary Supplement)

Placebo

Placebo Comparator

3g of a similar looking and tasting powder, twice daily

干预措施: placebo (Dietary Supplement)

结局指标

主要结局

Butyrate producing bacteria

时间窗: 6 months

abundance of butyrate producing bacteria

次要结局

  • soluble CD 14 concentration in serum(12 months)
  • lipopolysaccharide concentration in serum(12 months)
  • diaminooxidase concentration in serum(12 months)
  • zonulin concentration in stool(12 months)
  • Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS cog)(12 months)
  • Butyrate producing bacteria(12 months)
  • calprotectin concentration in stool(12 months)
  • clinician's interview-based impression of change with caregiver input (CIBIC+)(12 months)
  • lipopolysaccharide binding protein concentration in serum(12 months)
  • Barthel index(12 months)
  • bacterial DNA concentration in serum(12 months)
  • Mini mental state examination(12 months)
  • peptidoglycan concentration in serum(12 months)

研究者

发起方
Medical University of Graz
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验